Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to 2928.84%.

  • Kymera Therapeutics' EBITDA Margin fell 13662300.0% to 2928.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 124181.51%, marking a year-over-year increase of 1243677700.0%. This contributed to the annual value of 7251.32% for FY2024, which is 70699200.0% down from last year.
  • As of Q3 2025, Kymera Therapeutics' EBITDA Margin stood at 2928.84%, which was down 13662300.0% from 664.67% recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' EBITDA Margin peaked at 202.77% during Q4 2024, and registered a low of 2928.84% during Q3 2025.
  • In the last 5 years, Kymera Therapeutics' EBITDA Margin had a median value of 290.29% in 2025 and averaged 509.28%.
  • In the last 5 years, Kymera Therapeutics' EBITDA Margin surged by 2981200bps in 2021 and then tumbled by -13662300bps in 2025.
  • Kymera Therapeutics' EBITDA Margin (Quarter) stood at 225.3% in 2021, then increased by 7bps to 210.06% in 2022, then soared by 88bps to 26.04% in 2023, then skyrocketed by 879bps to 202.77% in 2024, then plummeted by -1544bps to 2928.84% in 2025.
  • Its EBITDA Margin was 2928.84% in Q3 2025, compared to 664.67% in Q2 2025 and 290.29% in Q1 2025.